Patients with obstructive hypertrophic cardiomyopathy (oHCM) have increased risk of arrhythmia, stroke, heart failure, and sudden death. Contemporary management of oHCM has decreased annual hospitalization and mortality rates, yet patients have worsening health-related quality of life due to impaired exercise capacity and persistent residual symptoms. Here we consider the design of clinical trials evaluating potential oHCM therapies in the context of SEQUOIA-HCM (Safety, Efficacy, and Quantitative Understanding of Obstruction Impact of Aficamten in HCM). This large, phase 3 trial is now fully enrolled (N = 282). Baseline characteristics reflect an ethnically diverse population with characteristics typical of patients encountered clinically with substantial functional and symptom burden. The study will assess the effect of aficamten vs placebo, in addition to standard-of-care medications, on functional capacity and symptoms over 24 weeks. Future clinical trials could model the approach in SEQUOIA-HCM to evaluate the effect of potential therapies on the burden of oHCM. (Safety, Efficacy, and Quantitative Understanding of Obstruction Impact of Aficamten in HCM [SEQUOIA-HCM]; NCT05186818).
Exercise Capacity in Patients With Obstructive Hypertrophic Cardiomyopathy / Coats, Caroline J.; Maron, Martin S.; Abraham, Theodore P.; Olivotto, Iacopo; Lee, Matthew M.Y.; Arad, Michael; Cardim, Nuno; Ma, Chang-Sheng; Choudhury, Lubna; Düngen, Hans-Dirk; Garcia-Pavia, Pablo; Hagège, Albert A.; Lewis, Gregory D.; Michels, Michelle; Oreziak, Artur; Owens, Anjali T.; Tfelt-Hansen, Jacob; Veselka, Josef; Watkins, Hugh C.; Heitner, Stephen B.; Jacoby, Daniel L.; Kupfer, Stuart; Malik, Fady I.; Meng, Lisa; Wohltman, Amy; Masri, Ahmad. - In: JACC. HEART FAILURE. - ISSN 2213-1779. - ELETTRONICO. - 12:(2024), pp. 199-215. [10.1016/j.jchf.2023.10.004]
Exercise Capacity in Patients With Obstructive Hypertrophic Cardiomyopathy
Olivotto, Iacopo;
2024
Abstract
Patients with obstructive hypertrophic cardiomyopathy (oHCM) have increased risk of arrhythmia, stroke, heart failure, and sudden death. Contemporary management of oHCM has decreased annual hospitalization and mortality rates, yet patients have worsening health-related quality of life due to impaired exercise capacity and persistent residual symptoms. Here we consider the design of clinical trials evaluating potential oHCM therapies in the context of SEQUOIA-HCM (Safety, Efficacy, and Quantitative Understanding of Obstruction Impact of Aficamten in HCM). This large, phase 3 trial is now fully enrolled (N = 282). Baseline characteristics reflect an ethnically diverse population with characteristics typical of patients encountered clinically with substantial functional and symptom burden. The study will assess the effect of aficamten vs placebo, in addition to standard-of-care medications, on functional capacity and symptoms over 24 weeks. Future clinical trials could model the approach in SEQUOIA-HCM to evaluate the effect of potential therapies on the burden of oHCM. (Safety, Efficacy, and Quantitative Understanding of Obstruction Impact of Aficamten in HCM [SEQUOIA-HCM]; NCT05186818).
| File | Dimensione | Formato | |
|---|---|---|---|
|
1-s2.0-S2213177923006893-main.pdf
accesso aperto
Tipologia:
Pdf editoriale (Version of record)
Licenza:
Open Access
Dimensione
1.33 MB
Formato
Adobe PDF
|
1.33 MB | Adobe PDF |
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
